Clozapine Levels as a Predictor for Therapeutic Response: A Systematic Review and Meta-Analysis

View/ Open
File version
Accepted Manuscript (AM)
Author(s)
Siskind, Dan
Sharma, Meghna
Pawar, Mrinal
Pearson, Ella
Wagner, Elias
Warren, Nicola
Kisely, Steve
Griffith University Author(s)
Year published
2021
Metadata
Show full item recordAbstract
OBJECTIVES: Clozapine levels may be a more useful predictor of therapeutic response than the dose, given the variability in clozapine metabolism between individuals. We therefore systematically reviewed and meta-analysed the impact of clozapine levels on response and/or relapse to provide guidance on optimal clozapine levels. METHODS: We systematically searched PubMed, PsycInfo and Embase for studies exploring clozapine levels and response and/or relapse. Our primary meta-analysis was rates of response above and below clozapine level thresholds of 350ng/mL and 600ng/mL. Secondary analyses were undertaken of mean clozapine ...
View more >OBJECTIVES: Clozapine levels may be a more useful predictor of therapeutic response than the dose, given the variability in clozapine metabolism between individuals. We therefore systematically reviewed and meta-analysed the impact of clozapine levels on response and/or relapse to provide guidance on optimal clozapine levels. METHODS: We systematically searched PubMed, PsycInfo and Embase for studies exploring clozapine levels and response and/or relapse. Our primary meta-analysis was rates of response above and below clozapine level thresholds of 350ng/mL and 600ng/mL. Secondary analyses were undertaken of mean clozapine levels, dose and concentration/dose (C/D) ratio and response and/or relapse. A meta-regression by study duration was conducted. RESULTS: Twenty studies met inclusion criteria. Clozapine levels above 350ng/mL were associated with statistically significantly higher rates of response (OR 2.27 95%CI 1.40-3.67, p<0.001), but not above 600ng/mL (OR 1.40 95%CI 0.85-2.31, p=0.19). Higher mean clozapine levels were associated with better rates of response (SMD 0.24, 95%CI 0.00-0.49, p=0.05), and lower rates of relapse (SMD -0.72, 95%CI -1.26 to -0.19, p=0.008). By contrast, neither clozapine dose nor C/D ratio were associated with differing rates of response. Similarly, study duration did not affect outcome. CONCLUSIONS: Our findings are in keeping with current guidelines that recommend targeting clozapine levels above 350ng/mL before augmentation is considered. As some clozapine associated ADRs are dose dependent, levels above 600ng/mL may have an unfavourable risk- benefit ratio.
View less >
View more >OBJECTIVES: Clozapine levels may be a more useful predictor of therapeutic response than the dose, given the variability in clozapine metabolism between individuals. We therefore systematically reviewed and meta-analysed the impact of clozapine levels on response and/or relapse to provide guidance on optimal clozapine levels. METHODS: We systematically searched PubMed, PsycInfo and Embase for studies exploring clozapine levels and response and/or relapse. Our primary meta-analysis was rates of response above and below clozapine level thresholds of 350ng/mL and 600ng/mL. Secondary analyses were undertaken of mean clozapine levels, dose and concentration/dose (C/D) ratio and response and/or relapse. A meta-regression by study duration was conducted. RESULTS: Twenty studies met inclusion criteria. Clozapine levels above 350ng/mL were associated with statistically significantly higher rates of response (OR 2.27 95%CI 1.40-3.67, p<0.001), but not above 600ng/mL (OR 1.40 95%CI 0.85-2.31, p=0.19). Higher mean clozapine levels were associated with better rates of response (SMD 0.24, 95%CI 0.00-0.49, p=0.05), and lower rates of relapse (SMD -0.72, 95%CI -1.26 to -0.19, p=0.008). By contrast, neither clozapine dose nor C/D ratio were associated with differing rates of response. Similarly, study duration did not affect outcome. CONCLUSIONS: Our findings are in keeping with current guidelines that recommend targeting clozapine levels above 350ng/mL before augmentation is considered. As some clozapine associated ADRs are dose dependent, levels above 600ng/mL may have an unfavourable risk- benefit ratio.
View less >
Journal Title
Acta Psychiatrica Scandinavica
Copyright Statement
© 2021 John Wiley and Sons. This is the peer reviewed version of the following article: Clozapine Levels as a Predictor for Therapeutic Response: A Systematic Review and Meta-Analysis, Acta Psychiatrica Scandinavica, 2021, which has been published in final form at https://doi.org/10.1111/acps.13361. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html)
Note
This publication has been entered as an advanced online version in Griffith Research Online.
Subject
Health sciences
Clozapine
Levels
Meta-Analysis
Relapse
Response